These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7652773)

  • 1. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine.
    Rehman MA; al-Sulaiman MH; Mousa DH; al-Hawas FA; Abdalla AH; Rassoul Z; al-Khader AA
    Transplantation; 1995 Aug; 60(4):397-9. PubMed ID: 7652773
    [No Abstract]   [Full Text] [Related]  

  • 2. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
    Illingworth DR; Erkelens DW; Keller U; Thompson GR; Tikkanen MJ
    Lancet; 1994 Jun; 343(8912):1554-5. PubMed ID: 7911877
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.
    Campana C; Iacona I; Regazzi MB; Gavazzi A; Perani G; Raddato V; Montemartini C; Viganò M
    Ann Pharmacother; 1995 Mar; 29(3):235-9. PubMed ID: 7606066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of low-density-lipoprotein lowering with statins.
    Leufkens HG; Herings RM; Urquhart J
    Lancet; 1994 Sep; 344(8923):683-4. PubMed ID: 7915368
    [No Abstract]   [Full Text] [Related]  

  • 5. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients.
    Lepre F; Rigby R; Hawley C; Saltissi D; Brown A; Walsh Z
    Clin Transplant; 1999 Dec; 13(6):520-5. PubMed ID: 10617243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment].
    Fiorini F; Patrone E; Ardu F; Castelluccio A
    Minerva Urol Nefrol; 1992; 44(2):165-8. PubMed ID: 1411867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipidemia in renal transplant recipients: natural history and response to treatment.
    Ong CS; Pollock CA; Caterson RJ; Mahony JF; Waugh DA; Ibels LS
    Medicine (Baltimore); 1994 Jul; 73(4):215-23. PubMed ID: 8041244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of low-density-lipoprotein lowering with statins.
    Seidel D; Cremer P
    Lancet; 1994 Sep; 344(8923):683. PubMed ID: 7915367
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of low-density-lipoprotein lowering with statins.
    Rosenson RS; Stein JH
    Lancet; 1994 Sep; 344(8923):683. PubMed ID: 7915366
    [No Abstract]   [Full Text] [Related]  

  • 11. [Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
    Martínez-Castelao A
    Med Clin (Barc); 1995 Nov; 105(18):719. PubMed ID: 8538262
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients.
    Martinez Hernandez BE; Persaud JW; Varghese Z; Moorhead JF
    Nephrol Dial Transplant; 1993; 8(7):637-41. PubMed ID: 8396749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of non-nephrotic hyperlipidaemia of chronic renal failure with simvastatin.
    Harris DC; Simons LA; Mitchell P; Stewart JH
    Med J Aust; 1991 Oct; 155(8):573. PubMed ID: 1943943
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience.
    Kandus A; Kovac D; Cerne D; Koselj M; Kaplan-Pavlovcic S; Buturović J; Ponikvar R; Kveder R; Lindic J; Bren AF
    Transplant Proc; 1998 Jun; 30(4):1307-9. PubMed ID: 9636530
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-benefit analysis of lipid lowering therapy.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 Jul; 17(7):974-5. PubMed ID: 8809507
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of 4S evidence on baseline lipid levels.
    Ravnskov U
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
    [No Abstract]   [Full Text] [Related]  

  • 17. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA
    Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.
    Arnadottir M; Eriksson LO; Thysell H; Karkas JD
    Nephron; 1993; 65(3):410-3. PubMed ID: 8289991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analysis of lipid lowering therapy.
    Jönsson B; Johannesson M
    Eur Heart J; 1997 Jan; 18(1):165-6. PubMed ID: 9049529
    [No Abstract]   [Full Text] [Related]  

  • 20. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
    Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
    Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.